Table 1.
Efficacy of vaccination with MVA-BN YF on disease in hamsters challenged with YF virus.
| Toxicity controls | Infected, treated | |||||||
|---|---|---|---|---|---|---|---|---|
| Treatment | Treatment dose, schedule | Alive/total | Serum alanine aminotransferase (ALT)a (IU/L) ± SD | Mean wt. changeb (g) ± SD | Alive/total | MDDc ± SD | Serum ALTa (IU/L) ± SD | Mean wt. changeb (g) ± SD |
| MVA-BN YF | 1 × 108 TCID50, −42, −14 dpi | – | – | – | 10/10 | >21.0 ± 0.0 | 61.9 ± 5.0 | 4.8 ± 4.2 |
| MVA-BN YF + Adj. | 1 × 108 TCID50, −42, −14 dpi | 3/3 | 62.3 ± 9.1 | 5.0 ± 2.0 | 10/10 | >21.0 ± 0.0 | 62.8 ± 8.3 | 4.6 ± 1.9 |
| YF-VAX | >5.5 × 104 pfu, −14 dpi | 3/3 | 66.4 ± 18.0 | 4.3 ± 3.1 | 10/10 | >21.0 ± 0.0 | 58.4 ± 6.6 | 4.6 ± 2.5 |
| Tris-buffered saline (TBS) + Adj. | −42, −14 dpi | 3/3 | 57.6 ± 5.9 | −0.3 ± 6.1 | 2/10 | 8.6 ± 1.3 | 151.6 ± 57.0 | −6.2 ± 7.3 |
| TBS | −42, −14 dpi | 3/3 | 62.5 ± 5.8 | 2.3 ± 1.2 | 6/15 | 8.4 ± 1.2 | 156.9 ± 42.3 | −8.9 ± 7.1 |
| Norm. controls | – | 3/3 | 64.3 ± 2.6 | 5.0 ± 0.0 | – | – | – | – |
aSerum ALT levels collected on 6 dpi.
bDifference between weight on 3 and 6 days post-virus challenge representing maximal weight change within this study.
cMean day to death of animals that succumb to disease during the experimental period of 21 days.